TIKCRO TECHNOLOGIES LTD. 
By TEL AVIV, Israel, March 31, 2014 /PRNewswire/ -- Tikcro Technologies Ltd. (OTC PK: TIKRF) today reported results for the fourth quarter and fiscal year ended December 31, 2013.
Net loss for the fourth quarter was $436,000, or $0.05 per diluted share. Results for the fourth quarter included a financial loss of approximately $313,000 that resulted primarily from the valuation of Tikcro's holdings in BioCancell Therapeutics, Inc. (TASE: BICL), a clinical-stage biopharmaceutical company engaged with the discovery, development, and commercialization of therapies for treating cancer-related diseases. Excluding this loss, net loss for the fourth quarter was $123,000 or $0.01 per diluted share.
Net profit for the full year ended December 31, 2013 was $8,000, or $0.00 per diluted share. Results for the full year ended December 31, 2013 included a financial gain of approximately $579,000 resulting primarily from the receipt of new shares of BioCancell Therapeutics, Inc., which were awarded to Tikcro pursuant to an arbitration award in July 2013. Excluding this gain, net loss for the full year ended December 31, 2013 was $571,000 or $0.07 per diluted share.
Tikcro supports early stage development in growth areas, with a focus on biotechnology, having projects in several fields originated by researchers from Israeli universities.
About Tikcro Technologies:
Tikcro is seeking early stage growth opportunities.
For more information, visit Tikcro website at www.tikcro.com.
Safe Harbor Statement
Certain of the statements contained herein may be considered forward-looking statements that involve risks and uncertainties including, but not limited to, risks related to our ability to raise financing and the business of BioCancell, including, but not limited to, the development, testing, regulatory approval and commercialization of its products, its intellectual property rights, its funding, its competition, its exposure to lawsuits and its dependence on key suppliers and personnel. Such risks and uncertainties are set forth in the Company's SEC reports, including the Company's Forms 20-F. Actual results may materially differ. Results of operations in any past period should not be considered indicative of the results to be expected for future periods. We undertake no duty to update any forward-looking information.
Tikcro Technologies Ltd.
Condensed Balance Sheets
(US dollars in thousands)
------------------------
December 31, December 31,
2013 2012
Unaudited Audited
--------- -------
Assets
Current assets
Cash and short-term marketable $9,120 $9,234
securities
Other receivables 14 31
Investment in BioCancell 397 243
--- ---
Total current assets 9,531 9,508
Total assets $9,531 $9,508
------ ------
Liabilities and Shareholders' Equity
Current liabilities
Other current liabilities $128 $171
---- ----
Shareholders' equity 9,403 9,337
----- -----
Total liabilities and shareholders' $9,531 $9,508
equity
Tikcro Technologies Ltd.
Statement of Operations
(US dollars in thousands, except per share data)
-----------------------------------------------
Three Months Ended Year Ended
December 31, December 31,
2013 2012 2013 2012
---- ---- ---- ----
Research and development $6 $8 $29 $40
expenses
General and administrative $117 $103 $542 $360
expenses, net
Total operating expenses 123 111 571 400
--- --- --- ---
Operating loss (123) (111) (571) (400)
Financial income (expenses), net (313) (5) 579 (158)
---- --- --- ----
Gain (Loss) before taxes (436) (116) 8 (558)
Tax expenses - 75 - (34)
--- --- --- ---
Net Gain (loss) $(436) $(41) $8 $(592)
Basic and diluted net gain $0.05 $(0.01) $0.00 $(0.07)
(loss) per share
Weighted average number of 8,804 8,692 8,755 8,649
shares used computing basic
and diluted gain/loss per share
For more information contact:
Investor Relations
Jeff Corbin / Rob Fink
KCSA Strategic Communications
(212) 896-1214 / 1206
jcorbin@kcsa.com / rfink@kcsa.com
SOURCE Tikcro Technologies Ltd.
